Stage-related outcome for thymic epithelial tumours

Background: Thymic epithelial tumours (TETs) are characterized by a wide variety of biological behaviors. Radical resection and stage are strong prognostic factors. Aim of this study is to review our Single Center Experience. Methods: One hundred and seventy-seven patients observed in the period from January 2000 to December 2016 were included in the study. Data regarding clinicopathologic features, treatment, and survival were collected. Stage-related clinical standpoints and therapeutic options were also evaluated. Results: Non-surgical treatment was primarily performed in 15 (8.47%), unresectable disease was intraoperatively found in 12 cases (7.4%). The analysis of 150 patients undergoing curative surgery revealed 70 stage I TET (46.66%), 49 stage II (32.66%), 19 stage III (12.66%), 6 stage IVa (4%) and 6 stage IVb (4%) at the first hospital admission. Histology identified 12 A thymoma (8%), 38 AB (25.33%), 24 B1 (16%), 50 B2 (33.33%), 19 B3 (12.66%) and 7 carcinomas (4.66%). The mean follow up time was 84.14 months (sd = 61.68 months). Disease relapse occurred in 13 patients (8.78%) at a mean period of 78.85 months (sd = 60.87 months) after surgery. Exitus due to thymoma happened in 6 cases (4.05%) after a mean survival of 56.02 months (sd = 25.17 months). The 5-year overall survival rate was 0.94 (95%CI 0.88-0.97) and the 5-year disease-free survival rate was 0.90 (95%CI 0.83-0.94). The 5-year overall survival rates were 96.1% (95% CI, 89.9-98.5%) for the early stages and 87.4% (95% CI, 65.6-95.8%) for the advanced stages (p = 0.670). The 5-year disease-free survival rates resulted being 98.8% (95% CI, 92.3-99.8%) for the early stages and 59.8% (95% CI, 37.8-76.2%) for the advanced stages (p < 0.001). Conclusions: Advanced stage TETs are characterized by higher mortality and recurrence rates. Although technically demanding, surgery, as part of multimodality therapy, could prolong survival. Iterative surgical treatment of recurrences is a viable option for selected patients. Trial registration: The study was approved by the Institutional Review Board of Perugia and Terni University Hospitals [Code T1003] and was retrospectively registered

Simulating the Cascading Effects of an Extreme Agricultural Production Shock: Global Implications of a Contemporary US Dust Bowl Event

Higher temperatures expected by midcentury increase the risk of shocks to crop production, while the interconnected nature of the current global food system functions to spread the impact of localized production shocks throughout the world. In this study, we analyze the global potential impact of a present-day event of equivalent magnitude to the US Dust Bowl, modeling the ways in which a sudden decline in US wheat production could cascade through the global network of agricultural trade. We use observations of country-level production, reserves, and trade data in a Food Shock Cascade model to explore trade adjustments and country-level inventory changes in response to a major, multiyear production decline. We find that a 4-year decline in wheat production of the same proportional magnitude as occurred during the Dust Bowl greatly reduces both wheat supply and reserves in the United States and propagates through the global trade network. By year 4 of the event, US wheat exports fall from 90.5 trillion kcal before the drought to 48 trillion to 52 trillion kcal, and the United States exhausts 94% of its reserves. As a result of reduced US exports, other countries meet their needs by leveraging their own reserves, leading to a 31% decline in wheat reserves globally. These findings demonstrate that an extreme production decline would lead to substantial supply shortfalls in both the United States and in other countries, where impacts outside the United States strongly depend on a country's reserves and on its relative position in the global trade network

TWO CASES OF NON-ALCOHOLIC WERNICKE ENCEPHALOPATHY SUCCESSFULLY TREATED BY THIAMINE REPLACEMENT: DIAGNOSTIC AND THERAPEUTIC CONSIDERATIONS

Wernicke\u2019s encephalopathy (WE) is an acute neurologi- cal disorder, due to a lack of thiamin (vitamin B1) which is observed mainly in alcoholic patients. Unfortunately, the syn- drome is underestimated in clinical practice and most often recognized only on autopsy, especially among non-alcoholics. The common clinical picture include mental status changes, ocular dysfunction, and gait ataxia. Treatment consists of timely thiamine replacement through intravenous infusion. We describe the case of two patients who developed a non-alcoholic WE post-surgical, regressed completely after intravenous infusion of thiamine. These cases suggest intere- sting diagnostic and therapeutic implications

BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors

In Chronic Myeloid Leukemia (CML), successful treatment requires accurate molecular monitoring to evaluate disease response and provide timely interventions for patients failing to achieve the desired outcomes. We wanted to determine whether measuring BCR-ABL1 mRNA doubling-times (DTs) could distinguish inconsequential rises in the oncogene’s expression from resistance to tyrosine kinase inhibitors (TKIs). Thus, we retrospectively examined BCR-ABL1 evolution in 305 chronic-phase CML patients receiving imatinib mesylate (IM) as a first line treatment. Patients were subdivided in two groups: those with a confirmed rise in BCR-ABL1 transcripts without MR3.0 loss and those failing IM. We found that the DTs of the former patients were significantly longer than those of patients developing IM resistance (57.80 vs. 41.45 days, p = 0.0114). Interestingly, the DT values of individuals failing second-generation (2G) TKIs after developing IM resistance were considerably shorter than those observed at the time of IM failure (27.20 vs. 41.45 days; p = 0.0035). We next wanted to establish if decreases in BCR-ABL1 transcripts would identify subjects likely to obtain deep molecular responses. We therefore analyzed the BCR-ABL1 halving-times (HTs) of a different cohort comprising 174 individuals receiving IM in first line and observed that, regardless of the time point selected for our analyses (6, 12, or 18 months), HTs were significantly shorter in subjects achieving superior molecular responses (p = 0.002 at 6 months; p < 0.001 at 12 months; p = 0.0099 at 18 months). Moreover, 50 patients receiving 2G TKIs as first line therapy and obtaining an MR3.0 (after 6 months; p = 0.003) or an MR4.0 (after 12 months; p = 0.019) displayed significantly shorter HTs than individuals lacking these molecular responses. Our findings suggest that BCR-ABL1 DTs and HTs are reliable tools to, respectively, identify subjects in MR3.0 that are failing their assigned TKI or to recognize patients likely to achieve deep molecular responses that should be considered for treatment discontinuation

Boron doped TiO2 catalysts for photocatalytic ozonation of aqueous mixtures of common pesticides: Diuron, o-phenylphenol, MCPA and terbuthylazine

Photocatalysts were characterized by ICP-EOS, N2 adsorption-desorption, XRD, XPS, and DR-UV-Vis spectroscopy. Four recalcitrant herbicides and pesticides (diuron, o-phenylphenol, 2-methyl-4-chlorophenoxyacetic acid (MCPA) and terbuthylazine) were subjected to degradation by ozonation, photolytic ozonation, photocatalysis and photocatalytic ozonation using the prepared catalysts under simulated solar irradiation in a laboratory scale system. The boron that was not incorporated to the TiO2 interstitial positions was unstable and leached to the solution. The washed B-doped TiO2 catalysts, with 0.5-0.8 wt.% of interstitial boron were more active than bare TiO2 for the removal and mineralization of the target compounds. The combination of ozonation and photocatalysis led to faster mineralization rates and allowed the complete removal of the pesticides below the regulatory standards. The B-doped catalyst was stable and maintained 75% mineralization after 3 consecutive runs

F-061 * A COMPARATIVE STUDY AMONG MINIATURIZED ULTRASOUND PROBES FOR PULMONARY NODULES DETECTION IN AN EX VIVO LUNG PERFUSION MODEL

n/

738–2 The Evolution of Therapy for Single Vessel Disease: A Treatment Comparison of Medicine, Angioplasty and Left Internal Mammary Artery Graft for Proximal Left Anterior Descending Disease

Saphenous vein bypass grafting for single vessel disease offers no survival or symptom relief advantage compared to medical therapy. Recent evidence suggests the use of the internal mammary artery or PTCA may be more beneficial than medicine. To examine the outcome of these treatment strategies, a retrospective analysis of prospectively collected data on 23,018 consecutive patients undergoing cardiac catheterization between April 1986 and February 1994 was performed. Of the 6,432 patients with single vessel disease, 1,222 had a proximal left anterior descending (LAD) stenosis>74% and no prior PTCA or CABG. A total of 289 were managed medically, 760 underwent PTCA, and 172 received a left internal mammary artery (LIMA) graft.Baseline demographic data and risk factor profiles were similar except for a higher incidence of diabetes (19 vs 15 vs 11%), history of MI (72 vs 58 vs 48%) CHF (18 vs 7 vs 8%), and total occlusions (44 vs 17 vs 7%) and lower incidence of unstable angina (40 vs 61 vs 64%) in the medical group as compared to PTCA and LIMA graft, respectively.Kaplan-Meier 6-year estimates:EventsMedicinePTCALIMAP-value–unadjusted survival (%)7885910.001–adjusted survival (%)8486900.24–event-free survival (%)5443720.0001ConclusionThere is a trend towards improved long-term survival in proximal LAD disease with a strategy of revascularization, particularly the LIMA graft. Furthermore, event-free survival is significantly improved with the LIMA graft as compared to medical therapy or PTCA